24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
UroGen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:20
The World Cup warning: Riots don’t start in the streets. They start online
18:07
“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal
14:18
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
13:32
“There is no better solution for Zim than the one we created”
More stories
Buzz
Most popular
Daily
Weekly
1
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
2
Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat
3
Unicorn Artlist to cut 200 jobs, 40% of workforce, despite surpassing $300 million ARR
4
"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"
5
Two years after a $2.7 billion return to Google, AI pioneer Noam Shazeer is leaving for OpenAI
More news
UroGen
5 stories about UroGen
”Exits are not a Strategy. I Never put up a ‘For Sale’ Sign”
23.05.20
|
Sophie Shulman and Golan Hazani
Arie Belldegrun, chairman of UroGen Pharma, talks about catching Covid-19 and gaining FDA approval in the midst of a global pandemic
Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen
24.04.19
|
CTech
The two companies will collaborate on the research of a “therapeutic area of mutual interest”
Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq
24.01.19
|
Lilach Baumer
Goldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering
Sustained Drug Release Company UroGen Submits New Drug Application to FDA
12.07.18
|
Amir Rosenbaum
Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections
Allergan Partners with Urine Incontinence Treatment Company
08.11.17
|
Lilach Baumer
Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen